A synthetic leucine zipper-based dimerization system for combining multiple promoter specificities.

Area of Science:

• Molecular Biology
• Gene Therapy
• Synthetic Biology

Background:

• Gene therapy requires precise control over therapeutic gene expression to target specific disease sites.
• Current methods often lack specificity, leading to off-target effects and limited efficacy.
• Synthetic promoters offer a promising strategy to restrict transgene transcription through multiple specificities.

Purpose of the Study:

• To develop a generally applicable strategy for precise gene expression control in gene therapy.
• To engineer an artificial heterodimeric transcription factor (DCTF system) for targeted gene delivery.
• To create a robust heterodimerization interface for high-affinity interactions without endogenous interference.

Main Methods:

• Development of a DCTF system utilizing an artificial heterodimeric transcription factor.
• Engineering of Fos and Jun leucine zippers for the dimerization interface.
• Combining cell type-specific and cell cycle-regulated transcription control.
• In vivo validation of the DCTF system's functionality.

Main Results:

• Demonstrated a functional DCTF system for precise transgene transcription control.
• Successfully engineered a high-affinity heterodimerization interface using Fos and Jun leucine zippers.
• Showcased the ability to combine cell type-specific and cell cycle-regulated transcription.
• Validated the system's efficacy in an in vivo setting.

Conclusions:

• The developed DCTF system provides a powerful tool for enhancing gene therapy specificity.
• Engineered leucine zippers offer a reliable method for creating artificial transcription factors.
• This strategy enables sophisticated control over gene expression for therapeutic applications.
• The DCTF system shows significant potential for in vivo gene therapy applications.